|
|
|
|
|
Sessions of Interest for the Upcoming 2021 Annual Meeting |
|
|
|
|
Plenary- Sunday - June 6th
|
|
|
|
Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).
Presented By: Michael Morris, MD
|
|
|
|
|
|
|
|
|
|
|
|
Discussion: (VISION) Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Presented By: Mary-Ellen Taplin, MD, FASCO
|
|
|
|
|
|
|
|
|
|
|
Friday - June 4th - On Demand
|
|
| Application of Genomic Testing Treatment for Patients with Prostate Cancer |
|
|
|
|
|
The Application of the Niche: Genomic Medicine in Prostate Trials and Treatments
Presented By: Veda N. Giri, MD
|
|
|
|
|
Medical Oncology Perspective: The Promise and Limitations of Precision Health in Metastatic Disease
Presented By: Franklin W. Huang, MD, Ph.D.
|
|
|
|
|
Urology Perspective: Application of Precision Health to High-Risk, Localized Disease
Presented By: Edward M. Schaeffer, MD, Ph.D.
|
|
|
|
|
| Evolution of Disparities in Prostate Cancer Treatment: Is This a New Normal? |
|
|
|
|
|
Prostate Cancer: The Case Study of Disparity in Cancer Care
Presented By: Bradley Curtis Carthon, MD, PhD
|
|
|
|
|
Differences in the Pattern of and Response to Treatment: Not Just Race
Presented By: Elisabeth I. Heath, MD, FACP
|
|
|
|
|
Genomic Disparities Across Gleason Scores
Presented By: Brandon Arvin Virgil Mahal, MD
|
|
|
|
|
| Poster Session - Prostate
|
|
|
|
|
|
Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC). HARPOON
Presented By: Johann de Bono, MD, MSc, PhD, FRCP, FMedSciD
|
|
|
|
|
COMBAT-CRPC: COncurrent adMinistration of Bipolar Androgen Therapy (BAT) and nivolumab in men with metastatic castration-resistant prostate cancer (mCRPC).
Presented By: Mark Markowski, MD, Ph.D.
|
|
|
|
|
Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).
Presented By: Scott T. Tagawa, MD, MS, FACP
|
|
|
|
|
PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.
Presented By: Frederic Pouliot, MD, Ph.D., FACSC
|
|
|
|
|
Evaluation of PSA progression after initiation of enzalutamide or abiraterone: Real-world data on metastatic castration-resistant prostate cancer (mCRPC).
Presented By: Fernando López-Campos, MD
|
|
|
|
|
Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).
Presented By: Neeraj Agarwal, MD
|
|
|
|
|
Impact of age on efficacy and safety of relugolix: A subgroup analysis from the randomized, phase 3 hero study versus leuprolide in men with advanced prostate cancer.
Presented By: Michael Cookson, MD, MMHC
|
|
|
|
|
A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.
Presented By: Michael J. Morris, MD
|
|
|
|
|
|
|
|
|
| Oligometastases in Prostate Cancer: How to Rationally Incorporate Metastasis-Directed Therapy into your Practice |
|
|
|
|
|
Radiation Oncologist's Perspective
Presented By: Phuoc T. Tran, MD, Ph.D.
|
|
|
|
|
International Perspective
Presented By: Nicholas D. James, MBBS, Ph.D.
|
|
|
|
|
Community Perspective
Presented By: Robert Given, MD
|
|
|
|
|
|
|
|
|
| Oral Abstract Session - Prostate
|
|
|
|
|
|
|
|
A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.
Presented By: Karim Fizazi, MD, Ph.D.
SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691).
Presented By: Neeraj Agarwal, MD
|
|
|
|
|
|
|
|
|
|
Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis.
Presented By: Silke Gillessen, MD
|
|
|
|
|
Ancestral characterization of the genomic landscape, comprehensive genomic profiling utilization, and treatment patterns may inform disparities in advanced prostate cancer: A large-scale analysis.
Presented By: Smruthy Sivakumar, MS
|
|
|
|
|
Association of increased intensity of prostate-specific antigen screening in younger African American men with improved prostate cancer outcomes.
Presented By: Edmund M. Qiao
|
|
|
|
|
A prospective ValiDation of the genomic classifier defines high-metastasis risk in a subset of African American men with early localized prostate cancer: VanDAAM study.
Presented By: Kosj Yamoah, MD, Ph.D.
|
|
|
|
|
Disparities in Prostate Cancer: Are We Making Progress?
Presented By: Peter C. Black, MD
|
|
|
|
|
| Beyond the Androgen Receptor: New Avengers in the Treatment of Castrate-Resistant Metastatic Cancer
|
|
|
|
|
|
Does the Treatment Sequence Matter? Resolving the Controversies
Presented By: Mark T. Fleming, MD
|
|
|
|
|
The New Avengers in the Treatment of Prostate Cancer
Presented By: Johann S. De Bono, FRCP, MB, MD, Ph.D.
|
|
|
|
|
Do Our Treatments Drive a New Resistant Mutational Phenotype?
Presented By: Ana Aparicio, MD
|
|
|
|
|
|
|
|
